Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
ChromaDex Corporation is a biotechnology business based in the US. ChromaDex Corporation shares (CDXC) are listed on the NASDAQ and all prices are listed in US Dollars. ChromaDex Corporation employs 110 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$6.38|
|52-week range||$4.36 - $16.82|
|50-day moving average||$6.90|
|200-day moving average||$8.31|
|Wall St. target price||$14.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.36|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||8.87%|
|1 month (2021-09-24)||-1.09%|
|3 months (2021-07-23)||-32.27%|
|6 months (2021-04-23)||-21.72%|
|1 year (2020-10-23)||32.37%|
|2 years (2019-10-25)||94.51%|
|3 years (2018-10-25)||80.23%|
|5 years (2016-10-25)||120.00%|
|Revenue TTM||$62 million|
|Gross profit TTM||$35.3 million|
|Return on assets TTM||-28.28%|
|Return on equity TTM||-73%|
|Market capitalisation||$433.7 million|
TTM: trailing 12 months
There are currently 3.5 million ChromaDex Corporation shares held short by investors – that's known as ChromaDex Corporation's "short interest". This figure is 4.9% down from 3.6 million last month.
There are a few different ways that this level of interest in shorting ChromaDex Corporation shares can be evaluated.
ChromaDex Corporation's "short interest ratio" (SIR) is the quantity of ChromaDex Corporation shares currently shorted divided by the average quantity of ChromaDex Corporation shares traded daily (recently around 559829.28802589). ChromaDex Corporation's SIR currently stands at 6.18. In other words for every 100,000 ChromaDex Corporation shares traded daily on the market, roughly 6180 shares are currently held short.
However ChromaDex Corporation's short interest can also be evaluated against the total number of ChromaDex Corporation shares, or, against the total number of tradable ChromaDex Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ChromaDex Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 ChromaDex Corporation shares in existence, roughly 50 shares are currently held short) or 0.0829% of the tradable shares (for every 100,000 tradable ChromaDex Corporation shares, roughly 83 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against ChromaDex Corporation.
Find out more about how you can short ChromaDex Corporation stock.
We're not expecting ChromaDex Corporation to pay a dividend over the next 12 months.
ChromaDex Corporation's shares were split on a 1:3 basis on 12 April 2016. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ChromaDex Corporation shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for ChromaDex Corporation shares which in turn could have impacted ChromaDex Corporation's share price.
Over the last 12 months, ChromaDex Corporation's shares have ranged in value from as little as $4.36 up to $16.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ChromaDex Corporation's is 1.7339. This would suggest that ChromaDex Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety ecommerce platform TRUNIAGEN. com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.